

GLAXOSMITHKLINE PLC

Form 6-K

January 17, 2017

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending 16 January 2017

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F ☒ Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No ☒

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Sir Andrew Witty

b) Position/status Chief Executive Officer

c) Initial notification/
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882

b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017.

c) Price(s) and volume(s)

Price(s)	Volume(s)
£15.7149	27.773

d) Aggregated information n/a (single transaction)

Aggregated volume Price

e) Date of the transaction 2017-01-12

f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Ms E Walmsley

b) Position/status CEO Designate

- c) Initial notification/
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882

b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017.

	Price(s)	Volume(s)
c) Price(s) and volume(s)	£15.7149	0.005

d) Aggregated information n/a (single transaction)

Aggregated volume Price

e) Date of the transaction 2017-01-12

f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr R G Connor

b) Position/status President, Global Manufacturing & Supply

- c) Initial notification/
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882

b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017.

	Price(s)	Volume(s)
c) Price(s) and volume(s)	£15.7149	33.594

d) Aggregated information n/a (single transaction)
Aggregated volume Price

e) Date of the transaction 2017-01-12

f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr L Debruyne

b) Position/status President, Global Vaccines

c) Initial notification/
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882

b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017.

c) Price(s) and volume(s)

Price(s)	Volume(s)
£15.7149	707.341

d) Aggregated information n/a (single transaction)
Aggregated volume Price

e) Date of the transaction 2017-01-12

f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr S Dingemans

b) Position/status Chief Financial Officer

c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882

b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017.

c) Price(s) and volume(s)

Price(s)	Volume(s)
£15.7149	121.722

d) Aggregated information	n/a (single transaction)
Aggregated volume Price	
e) Date of the transaction	2017-01-12
f) Place of the transaction	London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Mr S A Hussain
b) Position/status	President, Global Pharmaceuticals

c) Initial notification/ amendment	Initial notification
---------------------------------------	----------------------

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
--	---

b) Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017.
------------------------------	--

c) Price(s) and volume(s)	Price(s) Volume(s)
	£15.7149 646.179

d) Aggregated information	n/a (single transaction)
Aggregated volume Price	

e) Date of the transaction	2017-01-12
f) Place of the transaction	

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

London Stock Exchange
(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- | | |
|---------------------------------------|------------------------|
| a) Name | Mr D S Redfern |
| b) Position/status | Chief Strategy Officer |
| c) Initial notification/
amendment | Initial notification |

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- | | |
|---------|----------------------|
| a) Name | GlaxoSmithKline plc |
| b) LEI | 5493000HZTVUYLO1D793 |

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- | | |
|--|--|
| a) Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 |
|--|--|

- | | |
|------------------------------|--|
| b) Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017. |
|------------------------------|--|

- | | |
|---------------------------|-------------------------|
| c) Price(s) and volume(s) | Price(s) Volume(s) |
| | £15.7149 1,010.257 |

- | | |
|---------------------------|--------------------------|
| d) Aggregated information | n/a (single transaction) |
| Aggregated volume Price | |

- | | |
|-----------------------------|---------------------------------|
| e) Date of the transaction | 2017-01-12 |
| f) Place of the transaction | London Stock Exchange
(XLON) |

1. Details of PDMR/person closely associated with them ('PCA')

- | | |
|--------------------|-------------|
| a) Name | Ms C Thomas |
| b) Position/status | SVP, HR |

- c) Initial notification/
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882

b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017.

	Price(s)	Volume(s)
c) Price(s) and volume(s)	£15.7149	140.220

d) Aggregated information n/a (single transaction)

Aggregated volume Price

e) Date of the transaction 2017-01-12

f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr P C Thomson

b) Position/status SVP, Communications & Government Affairs

c) Initial notification/
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882

b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017.

	Price(s)	Volume(s)
c) Price(s) and volume(s)	£15.7149	453.092

d) Aggregated information n/a (single transaction)
Aggregated volume Price

e) Date of the transaction 2017-01-12

f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Dr M M Slaoui

b) Position/status Chairman, Global Vaccines

c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882

b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017.

c) Price(s) and volume(s)

Price(s)	Volume(s)
£15.7149	2.088

d) Aggregated information n/a (single transaction)
Aggregated volume Price

e) Date of the transaction 2017-01-12

f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Dr P J T Vallance

b) Position/status President, R&D

c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882

b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017.

c) Price(s) and volume(s)

Price(s)	Volume(s)
£15.7149	1,693.943

- | | |
|-----------------------------|---------------------------------|
| Aggregated information | n/a (single transaction) |
| d) Aggregated volume Price | |
| e) Date of the transaction | 2017-01-12 |
| f) Place of the transaction | London Stock Exchange
(XLON) |

1. Details of PDMR/person closely associated with them ('PCA')

- | | |
|--------------------|--|
| a) Name | Mrs K Thomson |
| b) Position/status | PCA of Mr P C Thomson
(SVP, Communications &
Government Affairs) |

- | | |
|---------------------------------------|----------------------|
| c) Initial notification/
amendment | Initial notification |
|---------------------------------------|----------------------|

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- | | |
|---------|----------------------|
| a) Name | GlaxoSmithKline plc |
| b) LEI | 5493000HZTVUYLO1D793 |

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- | | |
|--|--|
| a) Description of the financial instrument | Ordinary shares of 25 pence
each ('Ordinary Shares')
ISIN: GB000925288 |
|--|--|

- | | |
|------------------------------|--|
| b) Nature of the transaction | Acquisition of Ordinary
Shares following the
re-investment of dividends
paid to shareholders on 12
January 2017. |
|------------------------------|--|

- | | |
|---------------------------|-------------------------|
| c) Price(s) and volume(s) | Price(s) Volume(s) |
| | £15.7149 111.130 |

- | | |
|----------------------------|--------------------------|
| Aggregated information | n/a (single transaction) |
| d) Aggregated volume Price | |

- | | |
|----------------------------|------------|
| e) Date of the transaction | 2017-01-12 |
|----------------------------|------------|

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

Date: January 16, 2017

12